Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Public ClinicalTrials.gov record NCT00377429. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Single-Arm, Phase II Safety and Tolerability Study of Catumaxomab (Anti-EpCAM x Anti-CD3) in Women With Advanced Epithelial Ovarian Cancer After a Complete Response to Chemotherapy
Study identification
- NCT ID
- NCT00377429
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Neovii Biotech
- Industry
- Enrollment
- 47 participants
Conditions and interventions
Conditions
Interventions
- catumaxomab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2006
- Primary completion
- Jan 31, 2008
- Completion
- Jan 31, 2008
- Last update posted
- Jul 18, 2012
2006 – 2008
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Stanford University of Obstetrics and Gynecology | Stanford | California | 94305 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Gynecologic Oncology - Hinsdale | Hinsdale | Illinois | 60521 | — |
| Michiana Hematology Oncology P.C. | South Bend | Indiana | 46617 | — |
| James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| University of New Mexico | Albuquerque | New Mexico | 87131 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Magee-Women Hospital of UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| South Carolina Oncology Associates | Columbia | South Carolina | 29210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00377429, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2012 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00377429 live on ClinicalTrials.gov.